Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kobayashi, Masahisa
RISE, NCT05710692: Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients with Fabry Disease	Recruiting	2/3	18	Japan	PRX-102 1 mg/kg every 2 weeks, pegunigalsidase alfa, Recombinant human alpha galactosidase-A, PRX-102 2 mg/kg every 4 weeks	Chiesi Farmaceutici S.p.A., ICON plc	Fabry Disease	03/26	03/28
Nakanishi, Koichi
RISE, NCT05710692: Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients with Fabry Disease	Recruiting	2/3	18	Japan	PRX-102 1 mg/kg every 2 weeks, pegunigalsidase alfa, Recombinant human alpha galactosidase-A, PRX-102 2 mg/kg every 4 weeks	Chiesi Farmaceutici S.p.A., ICON plc	Fabry Disease	03/26	03/28
NCT06488924: An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB	Not yet recruiting	1/2	10	Japan	JR-446	JCR Pharmaceuticals Co., Ltd.	Mucopolysaccharidosis III-B	03/27	09/29